Artegraft

Artegraft, Inc. was founded in 1993 and provides surgeons with a biological alternative to artificial grafts. Compared to ePTFE and other synthetic graft materials, Artegraft's natural collagen matrix offers the advantage of long-term patency. Artegraft can also serve as a replacement for non-viable autologous fistulas. Available in lengths ranging from 15 to 50 cm and inner diameters of 4, 5, 6, 7, and 8 mm, Artegraft has been approved for use in the distal aorta for segmental bypass, arterial replacement, patch grafting, and in patients with absent or insufficient femoral veins, but it is primarily used as a hemodialysis graft.